Company Profile
Opexa Therapeutics
Company Overview
ABOUT OPEXA
Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publically-traded biotechnology company developing personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases, such as neuromyelitis optica (NMO). Opexa prides itself on having achieved a culture of scientific excellence, entrepreneurial pursuit and dedication to improve the life of those suffering from serious medical disorders. Each member of our team is committed to our goal of bringing novel therapies to market.
Our lead product, TcelnaTM, is an autologous T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. TcelnaTM is specifically tailored to each patient's unique T-cell immune response profile to myelin. As such, TcelnaTM is poised to be the first-ever, patient-specific therapy for MS.
Opexa is a fast-paced, dynamic, and exciting place to work. Working at Opexa provides individuals the opportunity to truly make a positive impact on the lives of those suffering from MS as well as offers significant opportunities for career growth.
EOE M/V/F/D
Benefits
company stock options
life insurance
FSA
HSA
EAP